Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorYunlong Wang
About this trial
Obese patients with atrial fibrillation (AF) have a high recurrence rate after catheter ablation, even at experienced centers. Weight reduction improves post-ablation outcomes, but lifestyle measures alone are difficult to sustain. Tirzepatide, a once-weekly GIP/GLP-1 dual receptor agonist, produces greater weight loss than GLP-1 monotherapy and may confer additional cardiometabolic benefits. This multicenter, randomized, open-label, parallel-group, superiority trial evaluates whether adding standardized tirzepatide treatment to a structured lifestyle intervention - compared with the lifestyle intervention alone - reduces AF recurrence within 1 year after ablation in obese patients.
Eligibility criteria
Qualifiers
Age ≥18 years and ≤75 years at the time of screening
Documented symptomatic paroxysmal AF or persistent AF, confirmed by 12-lead ECG, Holter monitoring, or cardiac monitoring device, with documented AF episode duration ≥7 days (for persistent AF) and total AF history duration ≤5 years
Failed response to or intolerance of at least one antiarrhythmic drug (AAD), or explicit patient preference for a rhythm control strategy
Undergoing catheter ablation for AF at a participating center, with confirmed successful restoration of sinus rhythm at the end of the procedure (as determined by the operator)
Disqualifiers
Long-standing persistent AF: continuous AF duration ≥5 years prior to enrollment
Prior catheter ablation for AF or atrial flutter at any time
Left atrial anteroposterior diameter >55 mm (by transthoracic echocardiography at screening)
Left ventricular ejection fraction (LVEF) <35% at screening
Trial design
Treatments tested in this trial
- Tirzepatide
- Structured Lifestyle Intervention
Treatment groups
710 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Yunlong Wang
Lead sponsor
Beijing Anzhen Hospital
Sponsor institution
Source ClinicalTrials.gov